Pricing Log in Create free account
Saturday 17 October 2026 Export MDRX’s income statement to Excel — free account

Veradigm Inc.

MDRX Healthcare Health Information Services

5.00 0.00 0.00%
Market cap
$654.5M
P/E
0.0×
Fwd P/E
−11.4×
Dividend yield
—
F-score
1/9
Altman Z
1.65
Beneish M
−3.57
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 3.88%

Capital & Financial Ratios $m

Market Cap 654.47
Revenue 588.02
Net Income (20.04)
Free Cash Flow 84.56
Net Debt (247.50)
Current Ratio 2.95 (at or above 1.5: strong)
Debt/Equity 0.20 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (11.40) (negative: loss-making)
P/S ratio 0.95
P/B ratio 0.55
Past 5Y EPS Growth —
This Y EPS Growth 1.52%
Next Y EPS Growth (5.49%) (below 0%: weak)
Next Y revenue growth (1.63%) (below 0%: weak)
Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.6×, against a ten-year median of 2.0×; over the ten years it ranged from −16.1× in 2021 to 34.5× in 2021.
P/S against its own 10 years 20.95%
10-year low 10-year high
P/B against its own 10 years 14.23%
10-year low 10-year high
EV/Sales against its own 10 years 14.57%
10-year low 10-year high
EV/FCF against its own 10 years 21.07%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2021 2022 2023 2024
Cash 135 448 447 294
Receivables 120 119 111 108
Inventory — — — —
Other 65 57 87 91
649 680 699 546
2021 2022 2023 2024
Payables 2 31 21 31
ST’ Debt 20 — 205 155
Other 511 — 12 15
488 230 446 422

Compound Annual Growth %

10y 5y 3y
Sales (8.06%) (18.30%) 0.97%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (4.58%) (8.95%) (16.08%)

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’24 — — — — 594
’23 — — — — 626
’22 143 151 152 143 588
’21 134 141 145 158 577
’20 381 369 366 — 556
’19 432 444 444 312 1,633
Fiscal quarters ending in the months shown.
value withheld pending a data check

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 — — — — —
’24 — — — — (20)
’23 — — — — 100
’22 69 (2) 28 21 117
’21 5 (201) 56 64 (77)
’20 (4) 23 53 (176) (104)
’19 6 (8) 36 12 46
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 — — — — —
’24 — — — — (50)
’23 — — — — 70
’22 59 (12) 20 17 85
’21 (4) (210) 45 50 (118)
’20 (33) (4) 30 (142) (149)
’19 (28) (39) 1 (8) (74)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 — — — — —
’24 — — — — (2.70)
’23 — — — — 0.39
’22 0.17 (0.54) 0.12 (0.51) (0.77)
’21 0.06 0.15 0.12 0.68 0.97
’20 (0.13) (0.05) 0.00 4.82 4.40
’19 (0.04) (0.90) (0.03) (0.12) (1.10)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Trend 2025e 2026e 2027e
Price, $
Price, $ Low — 9.80 10.24 8.54 8.75 4.56 13.05 13.59 9.34 5.01

Analyst estimates 2025–2027

Powerpack
High — 15.17 15.20 16.13 12.40 14.91 19.01 23.25 19.77 11.80
People
People Employees — 7,500 8,900 9,500 9,600 8,400 8,000 2,450 — 2,300
Revenue/emp, $m — 0.18 0.17 0.17 0.17 0.07 0.07 0.24 0.00 0.26
Income, $m
Income, $m Revenue — 1,386 1,498 1,618 1,633 556 577 588 626 594
Gross margin, % — 43.38 42.25 38.41 37.38 47.51 48.91 52.45 54.56 50.85
EBT — 32 (190) (62) (282) (13) 158 (63) 60 (215)
EBT margin, % — 2.28 (12.69) (3.84) (17.26) (2.26) 27.31 (10.66) 9.61 (36.16)
Net income — 3 (154) 408 (183) 696 140 (20) 49 (292)
Depreciation — 136 157 198 198 87 73 105 48 54
Per share, $
Per share, $ Revenue — 7.44 8.28 9.19 9.82 3.49 4.44 5.25 5.83 5.49
Earnings — (0.14) (1.09) 2.07 (1.10) 4.40 1.03 (0.77) 0.45 (2.71)
Cash flow — 1.44 1.55 0.39 0.28 (0.65) (0.59) 1.04 0.93 (0.19)
Capex — (0.67) (0.87) (0.76) (0.72) (0.28) (0.32) (0.29) (0.27) (0.28)
Free cash flow — 0.78 0.68 (0.37) (0.44) (0.94) (0.91) 0.75 0.65 (0.46)
Book value — 6.84 6.42 8.98 7.73 10.46 10.45 9.08 10.01 7.43
Shares, m — 186 181 176 166 159 130 112 107 108
Valuation, ×
Valuation, × P/E — 0.00 0.00 4.57 0.00 3.11 17.08 0.00 0.00 0.00
P/S — 1.47 1.81 1.05 1.00 4.14 4.16 3.28 2.05 1.86
P/B — 1.60 2.34 1.07 1.27 1.38 1.77 1.90 1.18 1.07
EV/Sales — 2.35 2.35 1.35 1.48 3.56 4.61 2.94 1.71 1.52
EV/FCF — 22.53 28.71 (33.07) (32.80) (13.27) (22.58) 20.47 11.89 10.57
Cash, $m
Cash, $m Operating cash flow — 269 279 68 46 (104) (77) 117 100 (20)
Capex — (124) (157) (134) (120) (45) (41) (32) (29) (30)
Free cash flow — 145 122 (66) (74) (149) (118) 85 70 (50)
Balance, $m
Balance, $m Working capital — (63) (33) 61 (369) 218 161 449 253 124
Total debt — 1,322 937 668 915 190 370 200 205 227
Net debt — 1,226 806 483 778 (348) 235 (248) (241) (67)
Shareholders’ equity — 1,273 1,160 1,580 1,285 1,666 1,360 1,018 1,074 804
Returns, %
Returns, % ROA — (0.79) (4.87) 9.82 (5.70) 22.73 5.34 (4.53) 3.20 (19.93)
ROIC — 1.69 0.40 (5.10) (3.02) 0.38 3.01 (2.20) 2.60 (16.52)
ROE — (1.91) (16.15) 26.55 (12.71) 47.17 9.22 (7.27) 4.70 (31.04)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2024 · latest quarter Dec 2022 · fundamentals updated 1 Oct 2026

Charts ten years each

Veradigm Inc. vs peers in Health Information Services (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
TDOC Teladoc Health, Inc. $1.1B — (loss-making) — (loss-making) −3.95% (below 0%: shrinking) n/m −27.07% (below 0%: shrinking) 68.56% (6.11%) Compare
HSTM HealthStream, Inc. $1.0B 46.0× 34.4× +12.55% (above 0%: growing) +27.78% (above 0%: growing) +362.71% (above 0%: growing) 65.35% 9.94% Compare
PHR Phreesia, Inc. $685.3M 64.4× 23.5× +10.41% (above 0%: growing) +200.00% (above 0%: growing) +43.51% (above 0%: growing) 66.64% 5.88% Compare
MDRX Veradigm Inc. $654.5M — (loss-making) — (loss-making) −9.74% (below 0%: shrinking) n/m −66.33% (below 0%: shrinking) 50.53% (37.41%)
SOPH SOPHiA GENETICS SA $620.6M — (loss-making) — (loss-making) +27.22% (above 0%: growing) n/m +6.50% (above 0%: growing) 64.61% (86.03%) Compare
WEAV Weave Communications, Inc. $594.5M — (loss-making) — (loss-making) +15.52% (above 0%: growing) n/m +94.33% (above 0%: growing) 72.03% (6.49%) Compare
EVH Evolent Health, Inc $550.6M — (loss-making) — (loss-making) +46.86% (above 0%: growing) n/m +58.67% (above 0%: growing) 12.39% (1.47%) Compare
NRC National Research Corporation $466.9M 80.6× 4.9× +3.98% (above 0%: growing) n/m +101.49% (above 0%: growing) 61.67% (9.15%) Compare
CTEV Claritev Corporation $404.4M — (loss-making) — (loss-making) +6.59% (above 0%: growing) n/m +49.10% (above 0%: growing) 73.72% 9.09% Compare
Median of peers $607.6M 64.4× 23.5× +11.48% — +53.89% 66.00% (3.79%)

All 51 Health Information Services stocks →

Veradigm Inc. (MDRX) key facts

  • Veradigm Inc. (MDRX) is a Health Information Services company in the Healthcare sector.
  • As of October 16, 2026, MDRX traded at $5.00, a market capitalization of $654.5 million.
  • Return on equity was −31.0% and debt-to-equity 0.20.
  • Its Piotroski F-score is 1 out of 9 and its Altman Z-score is 1.65 (distress zone) for fiscal 2024.

Source: company filings (standardised) and stockrow calculations · fundamentals updated Oct 1, 2026.

Veradigm Inc. (MDRX) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/MDRX · Data as of Oct 1, 2026 · For information only; not investment advice. · © 2026 stockrow.com